Polivy (Polatuzumab Vedotin-piiq)

Polivy is a CD79b-directed antibody-drug conjugate used in combination with medicine bendamustine and a rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, following at least a couple of prior therapies. 

Recommended Dosage: The recommended dose is 1.8 mg/kg as an intravenous infusion over 90 minutes every 21 days for 6 cycles along with bendamustine and a rituximab medicine. Subsequent infusions may be given over 30 minutes in case the previous infusion is tolerated. Premedicate with an antihistamine and antipyretic before polatuzumab vedotin injection. In case a planned dose is missed, administer as promptly as possible. Adjust the schedule of administration in order to maintain a 21-day interval b/w doses.

• Polatuzumab vedotin can cause peripheral neuropathy, including severe cases. Peripheral neuropathy appears as early as the first cycle of treatment and is a cumulative effect. Treatment may exacerbate pre-existing peripheral neuropathy. Assess patients for symptoms of peripheral neuropathy. 
• Polatuzumab vedotin can cause infusion-related reactions, including severe cases. Administer an antihistamine and antipyretic before the use of Polatuzumab, and monitor patients precisely throughout the infusion. If an infusion-related reaction appears, interrupt the infusion and institute apt medical management. 
• The polivy cancer treatment can cause serious or severe myelosuppression, including neutropenia, anemia and thrombocytopenia. Monitor CBC or complete blood counts throughout therapy. Cytopenias may require a delay, dose reduction, or interruption of therapy. Consider prophylactic G-CSFs administration.
• Fatal or serious infections, including opportunistic infections such as sepsis, pneumonia (including Pneumocystis jiroveci and other fungal pneumonia), cytomegalovirus infection, and herpesvirus infection have appeared in patients treated with Polatuzumab. Monitor patients during therapy for signs of infection. Administer prophylaxis for herpesvirus and Pneumocystis jiroveci pneumonia. 
• PML has been reported after treatment with Polatuzumab injection. Assess for new or  worsening neurological, cognitive, or behavioral changes. Hold this therapy and any concomitant chemotherapy in case PML is suspected, and permanently halt therapy if the diagnosis is confirmed.
• The polivy lymphoma may cause tumor lysis syndrome. Patients with high tumor burden and rapidly proliferative tumor may be at greater risk of tumor lysis syndrome. Monitor and consider appropriate measures, including tumor lysis syndrome prophylaxis.
• Severe cases of hepatotoxicity that were consistent with hepatocellular injury, including elevations of transaminases or bilirubin, have occurred in patients treated with medicine polivy. Preexisting liver disease, elevated baseline liver enzymes, and concomitant drugs may enhance the probability of hepatotoxicity. Monitor liver enzymes and bilirubin level.
• Depending on the mechanism of action and findings, this medicine can cause fetal harm if used by a pregnant woman. Females of reproductive age should use apt contraception during treatment and for at least three months after the final dose. 

Indian Pharma Network is proficient in sourcing Polivy (Polatuzumab Vedotin-piiq) from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide in countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.

Indian Pharma Network (IPN) is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address. Your health and well-being are our top priorities

What is the Generic Name for the trade name drug Polivy®?

Polatuzumab Vedotin-piiq is Generic Name for the trade name drug Polivy®.

What is the Manufacturer Name of Polivy®?

Polivy® is manufactured by Genentech, Inc.

Is Polivy® approved by the FDA?

Yes, Polivy® is approved by the FDA. Date of first approval: June 10, 2019

What is diffuse large B-cell lymphoma (DLBCL)?

DLBCL, is a type of aggressive lymphoma that affects B cells, which are WBCs that protect the body from infection. Although DLBCL may occur at any age, its occurrence increases with age. Most individuals are first diagnosed between the ages of 65 and 74. It can affect both men and women, although it is a bit more common in men.

What does relapsed or refractory (R/R) mean?

Relapse refers when the disease or the signs/symptoms of the disease come back after responding to previous therapy. Refractory refers to a disease that has not responded to previous therapy. Relapsed or refractory diffuse large B-cell lymphoma is often referred to as R/R DLBCL.

How is Polivy injection administered?

Polivy injection is administered as an IV infusion (directly into the vein) in a clinic or infusion center. Discuss with your health specialis in case you experience any adverse reactions during or after the infusion.

What are the most common side effects due to Polivy®?

The most common side effects during treatment were low blood cell counts, nerve problems in arms and legs, tiredness or lack of energy, diarrhea, nausea, decreased appetite, fever, and infections.

How much does Polivy 140 mg cost in India?

Polivy 140 mg injection cost in India is reasonable and can vary. In order to procure this DLBCL medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Polivy®?

Store refrigerated at 2-8°C (36-46°F) in original carton to protect from the light. Do not use beyond the expiration date shown on the carton. Neither freeze nor shake it.

Is it safe to buy Polivy® online from India?

Yes, You can buy Polivy injection online from India online authentically from https://theindianpharma.com/ if this product is not available or has not been approved in your home country.

What recent approvals or updates are there for Polivy?

Recently, the FDA has expanded the use of Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for first-line treatment of diffuse large B-cell lymphoma (DLBCL).

How effective is Polivy in treating DLBCL?

Clinical trials have shown that Polivy, when combined with other treatments like R-CHP, significantly improves progression-free survival and overall response rates in patients with DLBCL compared to standard therapies.

What should patients do to manage side effects of Polivy?

To manage common side effects such as peripheral neuropathy, patients should maintain open communication with their healthcare providers, potentially adjust dosages, and consider physical therapy. Managing gastrointestinal symptoms might involve dietary changes and medications to control nausea and diarrhea.

Is Polivy available in Asia?

Polivy injection is available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka. 

How can I get Polivy injection?

Indian Pharma Network (IPN) can facilitate the supply of Polivy (prescription medicine) to locations worldwide while adhering to legal requirements.

Can Polivy be used in patients with other types of lymphoma?

While Polivy is primarily approved for DLBCL, ongoing clinical trials are investigating its efficacy in other types of B-cell lymphomas. Patients should consult their healthcare provider to understand if Polivy could be an option for their specific condition.

What are the long-term outcomes for patients on Polivy?

Long-term outcomes for patients treated with Polivy are still being studied. However, initial data suggest improved survival rates and better disease management compared to standard therapies. Regular follow-up with healthcare providers is crucial to monitor health status and adjust treatment as necessary.

Where is Polivy available in India?

Polivy available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow,  Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc